Cancer Molecular Therapeutics Research Association (CMTRA) Annual Conference 2024

July 14-18th, 2024

Schedule and Program:

Sunday, July 14th 2024: Granlibakken GRANHALL	
4:00PM	**Arrival & Check-In**
6:00-7:00PM	**Dinner at Cedar House**
7:30-7:45PM	**Welcome & Introduction** **Martin McMahon, PhD** Huntsman Cancer Institute & Dept. of Dermatology, University of Utah, Salt Lake City, Utah **President CMTRA**
7:45-8:45PM	**KEYNOTE SPEAKER:** **Marcia Haigis, PhD** Professor, Department of Cell Biology, Harvard Medical School ***"The Role of Metabolites in Cancer, Immunity and Aging"***
9:00PM	**Welcome Reception**

Monday, July 15th 2024: MORNING	
7:30-8:15AM	**Breakfast**
8:30AM-12:30PM	**MORNING SESSION: Prostate Cancer** **GRANHALL** **Discussion Leader**: **Lori Friedman, PhD** Chief Scientific Officer of ORIC Pharmaceuticals; Vice-President CMTRA
8:30-8:40AM	**Introduction**
8:40-9:10AM	**Amina Zoubeidi, PhD** Canada Research Chair in Cancer Therapy Resistance & Professor, University of British Columbia ***"Lineage Plasticity in Prostate Cancer: From Biology to Therapy"***
9:10-9:30AM	**Discussion**
9:30-10:00AM	**Melissa Junttila, PhD** Vice President, Head of Biology at ORIC Pharmaceuticals ***"The Fate of Prostate Cancer Cells Treated with PRC2 Inhibitors Underlies Combination Synergy Observe with AR Pathway Inhibitors"***
10:00-10:20AM	**Discussion**
10:20-10:40AM	**Coffee Break**
10:40-11:10AM	**David Quigley, PhD** Asst. Professor, Dept. of Urology, UC San Francisco, ***"Genomic And Epigenomic Mechanisms of Targeted Therapy Resistance in Prostate Cancer"***

11:10-11:30AM	**Discussion**
11:30AM-Noon	**Mark Rolfe, PhD** Senior Vice President, Bristol Myers Squibb, Senior Vice President | Research Oncogenesis Thematic Research Center ***"Discovery of BMS-986365 a Ligand-Directed Androgen Receptor Degrader with a Dual Mechanism-of-Action and Potential for the Treatment of Advanced Prostate Cancer"***
Noon-12:20PM	**Discussion**
12:30-1:30PM	**Lunch**
1:30-4:45PM	**OPEN NETWORKING AFTERNOON** **See activities Handout**
5:00-6:30PM	**Poster Session and Social**
6:30-7:30PM	**Dinner**
Monday, July 15th 2024: EVENING	
7:30-9:45PM	**EVENING SESSION: Artificial Intelligence/Machine Learning in Oncology R&D** **Discussion Leader: Eli Wallace, PhD** Chief Scientific Officer BridgeBio; Secretary CMTRA
7:30-7:45PM	**Introduction**
7:45-8:15PM	**Pat Walters, PhD** Chief Data Officer at Relay Therapeutics ***"Artificial Intelligence in Drug Discovery – Revolution, Evolution, or Complete Nonsense"***
8:15-8:45PM	**Discussion**
8:45-9:15PM	**Lingle Wang, PhD** Vice President, Scientific Development at Schrodinger, Inc. ***"Accelerating Drug Discovery with Digital Chemistry: When Physics meets AI"***
9:15-9:45PM	**Discussion**
9:45PM	**Social**
Tuesday, July 16th 2024, MORNING	
7:30-8:15AM	**Breakfast**
8:30AM-Noon	**MORNING SESSION: Chemical Biology in Oncology** **Discussion Leader: Bob Abraham, PhD**

8:30-8:45AM	**Introduction**
8:45-9:15AM	**Gerry Crabtree, MD** Professor of Pathology & Developmental Biology, Stanford University & HHMI Investigator ***"Rewiring Cancer Drivers to Activate Pathways of Programmed Cell Death"***
9:15-9:40AM	**Discussion**
9:40-10:00AM	***Group Photograph* and Coffee Break**
10:00–10:30AM	**Ben Cravatt, PhD** Professor, Norton B. Gilula Chair in Biology and Chemistry, Scripps Institute ***"Activity-Based Proteomics – Cancer Target and Ligand Discovery on a Global Scale"***
10:30-11:00AM	**Discussion**
11:00-11:30AM	**Michelle Arkin, PhD** Professor and Chair, Pharmaceutical Chemistry, U.C. San Francisco & Executive Director, Small Molecule Discovery Center ***"Stabilizing Chaperone/Client Interactions as an Alternative Approach To Cancer Drug Discovery"***
11:30-Noon	**Discussion**
12:00-1:00PM	**Lunch**
1:00-4:45PM	**OPEN NETWORKING AFTERNOON**
5:00-6:30PM	**Poster Session and Social**
Tuesday, July 16th 2024: EVENING	
7:30-9:45PM	**EVENING SESSION: Lineage Infidelity in Cancer** **Discussion Leader: Aria Vaishnavi, PhD**
7:30-7:45PM	**Introduction**
7:45-8:15PM	**Laura Attardi, PhD** Professor, Dept. of Radiation Oncology, Stanford University ***"Deciphering How TP53 Governs Cell State Transitions in Lung and Pancreatic Cancer"***
8:15-8:45PM	**Discussion**
8:45-9:15PM	**Rosie Sears, PhD**

	Professor of Molecular and Medical Genetics, School of Medicine Co-Director, Brenden-Colson Center for Pancreatic Care, School of Medicine Krista L. Lake Chair in Cancer Research ***"Aggressive Phenotypes and Therapeutic Targets In Liver Metastatic Pancreatic Cancer"***
9:15-9:40PM	**Discussion**
9:40PM	**Social**
Wednesday, July 17th 2024	
7:30-8:15AM	**Breakfast**
8:30AM-12:00PM	**MORNING SESSION: Targeted Biologic Radio-Ligand Therapy** **Discussion Leader**: **Markus Reschke, PhD**
8:30-8:45AM	**Introduction**
8:45-9:15AM	**Markus Reschke, PhD** Executive Director, Head of RLT Drug Discovery, Novartis Biomedical Research Oncology ***"The Radioligand Therapy Platform at Novartis: Challenges and Opportunities"***
9:15-9:40AM	**Discussion**
9:40-10:00AM	**Coffee Break**
10:00-10:30AM	**Mike Evans, PhD** Professor, Dept. of Radiology & Biomedical Imaging, U.C. San Francisco. ***"Applying Chemical Biology to Maximize the Antitumor Effects of Targeted Radiotherapies"***
10:30-10:55AM	**Discussion**
11:00-11:30AM	**Anna Wu, PhD** Chair and Professor, Department of Immunology & Theranostics, City of Hope, ***"Engineered Antibody Fragments Targeting PSCA For Radio-Ligand Therapy of Pancreatic and Prostate Cancer"***
11:30-11:55AM	**Discussion**
Noon-1:30PM	**Lunch**
1:30-2:30PM	**Panel Discussion – Voices from academia, industry and venture capital on the current state and future of oncology research, drug discovery and development** **Discussion Leader**: **Eli Wallace, PhD**

2:30-3:00PM	**Coffee Break**
3:00-5:00PM	**AFTERNOON SESSION: Synthetic Lethality** **Discussion Leader: Emma Lees, PhD**
3:00-3:15PM	**Introduction**
3:15-3:45PM	**Pete Olson, PhD** Vice President, Research Bristol Myers Squibb ***"Exploiting Synthetic Lethality to Develop a Precision Medicine for CDKN2A/MTAP-deleted Cancers Using an MTA-cooperative PRMT5 Inhibitor"***
3:45-4:10PM	**Discussion**
4:10–4:40PM	**Matt Patricelli, PhD** Chief Scientific Officer, Vividion Therapeutics ***"Chemoproteomic Discovery of a Covalent Allosteric Inhibitor of WRN Helicase"***
4:40-5:10PM	**Discussion**
6:00-7:00PM	**Dinner**
7:15-8:15PM	**KEYNOTE SPEAKER:** **Alan Ashworth, PhD** President, Helen Diller Family Comprehensive Cancer Center Senior & E. Dixon Heise Distinguished Professor in Oncology, U.C. San Francisco ***"Synthetic Lethal and Combinatorial Approaches to Cancer Therapy"***
8:30-10:00PM	**Farewell Reception**

Thursday, July 18th 2024	
11:00AM	**Check out by 11:00AM**

IMPORTANT NOTICE: By attending this conference, you agree to respect the confidentiality of the proceedings. Specifically, photographing or recording of sessions, posters or discussions is not permitted. Reference to material presented or discussed may not be included in any publication. Permission to cite information may subsequently be obtained directly from the presenter and is beyond the control of the meeting organizers.

THIS MEETING WOULD NOT BE POSSIBLE WITHOUT THE GENEROUS CONTRIBUTIONS FROM OUR MANY FRIENDS AND COLLEAGUES